Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease
暂无分享,去创建一个
L. Defebvre | X. Thuru | G. Baille | W. Vandenberghe | M. Chartier-Harlin | E. Mutez | B. Sablonnière | S. Eddarkaoui | V. Huin | J. Taymans | M. Tir | A. Marchand | C. Deldycke | L. Buée | Romain Magnez | Sébastien Carrier | Liesel Goveas | Gaëlle Vermeersch | Ilda Coku
[1] Huidong Tang,et al. A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.
[2] X. Thuru,et al. A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively , 2022, Cells.
[3] M. Bolliger,et al. Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation , 2021, Neurobiology of Disease.
[4] A. Myasnikov,et al. Structural analysis of the full-length human LRRK2 , 2021, Cell.
[5] M. Chartier-Harlin,et al. Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells , 2021, Cells.
[6] E. Tolosa,et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils , 2021, Acta Neuropathologica.
[7] E. Tan,et al. Identification of Targets from LRRK2 Rescue Phenotypes , 2021, Cells.
[8] T. Iwatsubo,et al. The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System , 2020, Frontiers in Neuroscience.
[9] D. Alessi,et al. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease , 2020, Current opinion in cell biology.
[10] E. Tolosa,et al. LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.
[11] B. Baker,et al. LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain , 2019, Small GTPases.
[12] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[13] A. Kishore,et al. Understanding the role of genetic variability in LRRK2 in Indian population , 2018, Movement disorders : official journal of the Movement Disorder Society.
[14] M. Cookson,et al. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network , 2018, Human molecular genetics.
[15] S. Pfeffer,et al. Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase , 2017, The EMBO journal.
[16] L. Bubacco,et al. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2 , 2017, Human molecular genetics.
[17] G. Hadjigeorgiou,et al. Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations , 2016, PloS one.
[18] G. Jarvik,et al. Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. , 2016, American journal of human genetics.
[19] Matthias Mann,et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.
[20] S. Cragg,et al. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function , 2016, Human molecular genetics.
[21] Lynn A. Hyde,et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[22] G. Deuschl,et al. MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[23] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[24] R. Nichols,et al. LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status , 2014, Front. Mol. Neurosci..
[25] M. Farrer,et al. Advances in the genetics of Parkinson disease , 2013, Nature Reviews Neurology.
[26] K. Scearce-Levie,et al. Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations , 2012, Science Translational Medicine.
[27] A. Grünewald,et al. Genetics of Parkinson's Disease , 2011, Seminars in neurology.
[28] A. Prescott,et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization , 2010, The Biochemical journal.
[29] J. Jankovic,et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a chinese multicenter study , 2010, Human mutation.
[30] M. Goldberg,et al. Regulation of LRRK2 Stability by the E3 Ubiquitin Ligase CHIP , 2009, PloS one.
[31] W. Dauer,et al. The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration , 2009, The Journal of Neuroscience.
[32] J. Johnson,et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants , 2007, European journal of neurology.
[33] H. Braak,et al. 100 years of Lewy pathology , 2013, Nature Reviews Neurology.
[34] Christine Klein,et al. Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.